TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21054770

Group type: EXPERIMENTAL
Intervention: Interval training (n=140; 60%-79% maximum heart rate, 45 to 60 minutes for 8 weeks)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Continuous training (n=112; 60%-79% maximum heart rate, 45 to 60 minutes for 8 weeks)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group (n=105; sedentary)
Number of subjects: 357
Study: 16178191

Group type: EXPERIMENTAL
Intervention: Adhesion present (136 patients)
Number of subjects: 251

Group type: COMPARATOR
Intervention: No adhesion (87 patients)
Number of subjects: 251
Study: 12047962

Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab every 8 weeks (group II)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: 10 mg/kg infliximab every 8 weeks (group III)
Number of subjects: 573

Group type: COMPARATOR
Intervention: Placebo (group I)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab (group II and III combined)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab (group II and III)
Number of subjects: 573

Group type: COMPARATOR
Intervention: 5 mg/kg infliximab (group I)
Number of subjects: 573
Study: 9565821

Group type: EXPERIMENTAL
Intervention: 1 mg beta-carotene/kg BW/d up to 50 kg BW, 50 mg beta-carotene/d for 12 weeks, then 10 mg beta-carotene/d for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo with starch
Number of subjects: 24
Study: 7943836

Group type: EXPERIMENTAL
Intervention: Halothane (0.15 minimum alveolar concentration)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no halothane)
Number of subjects: 14
Study: 3369709

Group type: EXPERIMENTAL
Intervention: Antibiotics plus kallikrein (600 units per day for 3 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Antibiotics plus kallikrein
Number of subjects: 120
Study: 12540081

Group type: EXPERIMENTAL
Intervention: Bledsoe Diabetic Conformer Boot
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fiberglass total contact cast
Number of subjects: 18
Study: 30860412

Group type: EXPERIMENTAL
Intervention: Short-foot exercises group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 29986935

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (thrombectomy)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: TICI 2B-3 reperfusion
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: TICI scores
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: TICI 3 patients
Number of subjects: 92
Study: 27117004

Group type: EXPERIMENTAL
Intervention: Xylitol (50 g in 300 ml of water)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Erythritol (75 g in 300 ml of water)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glucose (75 g in 300 ml of water)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 20
Study: 24979518

Group type: EXPERIMENTAL
Intervention: Sevoflurane (2-2.5%) in Group 1
Number of subjects: 60

Group type: COMPARATOR
Intervention: TIVA in Group 3
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane (2-2.5%) in Group 2
Number of subjects: 60
Study: 21300447

Group type: EXPERIMENTAL
Intervention: Accelerated Radiotherapy (AR)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Accelerated Radiotherapy plus Carbogen and Nicotinamide (ARCON)
Number of subjects: 345
Study: 19865105

Group type: EXPERIMENTAL
Intervention: Inosine treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 16
Study: 19597407

Group type: EXPERIMENTAL
Intervention: Anesthesia with remifentanil (group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General anesthesia (group A)
Number of subjects: 100
Study: 15955756

Group type: EXPERIMENTAL
Intervention: Mobile stroke team intervention
Number of subjects: 308

Group type: COMPARATOR
Intervention: Control group (general ward-based care)
Number of subjects: 308
Study: 12709856

Group type: EXPERIMENTAL
Intervention: Noninstrumented posterolateral fusion (PLF)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Instrumented posterolateral fusion (VSP)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: 360 fusion (interbody fusion with solid autogenous bone grafts)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Comparison of '360' with PLF
Number of subjects: 211

Group type: COMPARATOR
Intervention: Comparison of '360' with VSP
Number of subjects: 211

Group type: COMPARATOR
Intervention: Comparison of instrumentation (VSP and 360) with non-instrumented fusion (PLF)
Number of subjects: 211
Study: 10472224

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) inflated to 7 cm H2O (group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) inflated to 15 cm H2O (group III)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Face mask (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 60
Study: 8608288

Group type: EXPERIMENTAL
Intervention: Routine care plus support from breast care nurse
Number of subjects: 272

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Routine care plus support from voluntary organisation
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Routine care plus support from nurse and organisation
Number of subjects: 272
Study: 1912128

Group type: EXPERIMENTAL
Intervention: Melatonin (75 mg per os)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 6429405

Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 0
Study: 30924714

Group type: EXPERIMENTAL
Intervention: IMPACT intervention (13 training modules)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 156
Study: 31388185

Group type: EXPERIMENTAL
Intervention: Intratumoural CD8+ density
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Tumour CD8A expression
Number of subjects: 1804
Study: 30328470

Group type: EXPERIMENTAL
Intervention: Typical rehabilitation with respiratory rehabilitation
Number of subjects: 63

Group type: COMPARATOR
Intervention: Typical rehabilitation
Number of subjects: 63
Study: 26611782

Group type: EXPERIMENTAL
Intervention: Oral metronidazole 500 mg twice daily for 7 days
Number of subjects: 1365

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 1365
Study: 24499136

Group type: EXPERIMENTAL
Intervention: Ambrisentan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22589500

Group type: EXPERIMENTAL
Intervention: Usual care provided by memory clinic
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual care provided by general practitioner
Number of subjects: 175
Study: 20709302

Group type: EXPERIMENTAL
Intervention: Higher intakes of calcium, skim milk, and dairy products
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Each additional cup of skim milk consumed per day
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Dietary pattern of high dairy and low fat intake
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Higher intakes of skim milk, dairy foods, calcium, animal protein, and potassium
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Higher intakes of calcium, vitamin D, skim milk, dairy foods, potassium, and a dietary pattern of high dairy and low fat
Number of subjects: 125
Study: 17547799

Group type: EXPERIMENTAL
Intervention: Cypher stents (sirolimus-eluting)
Number of subjects: 3345

Group type: COMPARATOR
Intervention: TAXUS stents (paclitaxel-eluting)
Number of subjects: 3345

Group type: EXPERIMENTAL
Intervention: Overall DES thrombosis
Number of subjects: 3345

Group type: EXPERIMENTAL
Intervention: Overall causes of thrombosis
Number of subjects: 3345
Study: 16362147

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily (n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly (open-label phase)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo followed by Alendronate 70 mg once weekly (open-label phase)
Number of subjects: 22
Study: 11822111

Group type: EXPERIMENTAL
Intervention: Classroom-based DHE lesson plus two small group sessions
Number of subjects: 449

Group type: COMPARATOR
Intervention: Single classroom-based DHE lesson
Number of subjects: 449
Study: 9726393

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for 3 weeks
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for 6 weeks
Number of subjects: 227

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 3 weeks
Number of subjects: 227

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 6 weeks
Number of subjects: 227
Study: 7506225

Group type: EXPERIMENTAL
Intervention: 3 MU of recombinant interferon-alpha 2b three times a week for 12 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Not treated (control group)
Number of subjects: 45
Study: 2662741

Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC) 30 U
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31913826

Group type: EXPERIMENTAL
Intervention: In-house developed natural rubber CPR manikin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Commercial manikin
Number of subjects: 40
Study: 26360825

Group type: EXPERIMENTAL
Intervention: HOT meal containing 5.82 mg total capsaicinoids
Number of subjects: 0

Group type: COMPARATOR
Intervention: CON meal with no chilli
Number of subjects: 0
Study: 25751199

Group type: EXPERIMENTAL
Intervention: Single-size diaphragm with acid-buffering gel
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Single-size diaphragm with nonoxynol-9
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard diaphragm (historical control)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Single-size diaphragm
Number of subjects: 450
Study: 23524437

Group type: EXPERIMENTAL
Intervention: Topical application of melatonin (1% orabase cream formula) once daily for 20 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topical application of melatonin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 30
Study: 20878389

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 272

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 272
Study: 19154509

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 50
Study: 17182805

Group type: EXPERIMENTAL
Intervention: Moderate consumption of olive oil (25 mL/d)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Olive oil intervention
Number of subjects: 160
Study: 15527429

Group type: COMPARATOR
Intervention: Unilateral tap water iontophoresis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unilateral glycopyrrolate iontophoresis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bilateral glycopyrrolate iontophoresis
Number of subjects: 20
Study: 11110999

Group type: EXPERIMENTAL
Intervention: Taste (sip-and-spit energy-dense preload)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Taste/kcal (energy-dense preload)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water (water preload)
Number of subjects: 24
Study: 8936611

Group type: EXPERIMENTAL
Intervention: Young Diabetics
Number of subjects: 121

Group type: COMPARATOR
Intervention: Non-Diabetics (Young)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Elderly Diabetics
Number of subjects: 121

Group type: COMPARATOR
Intervention: Non-Diabetics (Elderly)
Number of subjects: 121
Study: 1583252

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 micrograms once daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 44
Study: 3990300

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 31076272

Group type: EXPERIMENTAL
Intervention: Oral and locally administered corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal steroid spray and antihistamine drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olfactory training using odorants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olfactory testing
Number of subjects: 0
Study: 29321008

Group type: EXPERIMENTAL
Intervention: Standard quitline services plus Pathways to Freedom (PTF) intervention
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Quitline services plus a standard tobacco cessation DVD (attention control)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Quitline services alone (usual care)
Number of subjects: 1050
Study: 26956041

Group type: EXPERIMENTAL
Intervention: Two-session cognitive-behavioral enhanced intervention (n=147)
Number of subjects: 296

Group type: COMPARATOR
Intervention: One-session didactic information-only minimal intervention (n=149)
Number of subjects: 296
Study: 24837690

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg once a day for up to 21 days
Number of subjects: 803

Group type: COMPARATOR
Intervention: Placebo once a day for up to 21 days
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 803

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study: 23009311

Group type: EXPERIMENTAL
Intervention: Urea 5% with arginine and carnosine (Ureadin Rx Db, ISDIN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glycerol-based emollient cream (Dexeryl, Pierre Fabre)
Number of subjects: 40
Study: 19901309

Group type: EXPERIMENTAL
Intervention: Medical assistant referral arm
Number of subjects: 864

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 864
Study: 18090458

Group type: EXPERIMENTAL
Intervention: Stalevo 50 (LCE50; 50/12.5/200 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Stalevo 100 (LCE100; 100/25/200 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Stalevo 150 (LCE150; 150/37.5/200 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sinemet 100 (LC100; 100/25 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All treatments (LCE50, LCE100, LCE150, LC100)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: LCE100 and LCE150
Number of subjects: 28
Study: 15096909

Group type: EXPERIMENTAL
Intervention: Cyclazocine (0.2, 0.4 and 0.8 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hydromorphone (5 and 15 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cyclazocine (0 mg pretreatment)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cocaine (100 mg intranasal)
Number of subjects: 13
Study: 12880053

Group type: EXPERIMENTAL
Intervention: Lag-click condition at 43, 58, or 73 dB
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Single-click condition
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Interclick interval (ICI) varied from 0.3 to 10 ms
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Data from three highly experienced observers
Number of subjects: 127
Study: 10474283

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 to 20 mg/day
Number of subjects: 828

Group type: COMPARATOR
Intervention: Haloperidol 5 to 20 mg/day
Number of subjects: 828
Study: 8557891

Group type: EXPERIMENTAL
Intervention: Stent group
Number of subjects: 516

Group type: COMPARATOR
Intervention: Balloon angioplasty group
Number of subjects: 516
Study: 1987616

Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141

Group type: COMPARATOR
Intervention: UDCA or Placebo
Number of subjects: 141
Study: 6138082

Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg (oral)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Midazolam 20 mg (oral)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Midazolam 40 mg (oral)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Midazolam 0.15 mg kg‐1 (intravenous)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3890448

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (Efamol)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 99
Study: 31874050

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D3 pearl once weekly for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo once weekly for 12 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (Vitamin D and Placebo)
Number of subjects: 44
Study: 29891272

Group type: EXPERIMENTAL
Intervention: Negatively framed questionnaires (PHQ-2, PCS-4, PROMIS depression CAT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Positively framed questionnaires (PSEQ-2)
Number of subjects: 134
Study: 27753609

Group type: EXPERIMENTAL
Intervention: FP plus Bev (arm A)
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Bev alone (arm B)
Number of subjects: 837

Group type: COMPARATOR
Intervention: No active treatment (arm C)
Number of subjects: 837
Study: 23939383

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced magnetic resonance angiography (MRA)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Intra-arterial digital subtraction angiography (DSA)
Number of subjects: 79
Study: 23299716

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis NCC2818
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20885298

Group type: EXPERIMENTAL
Intervention: tinzaparin (175 IU/kg/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: acenocoumarol
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: tinzaparin
Number of subjects: 102
Study: 18283386

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/day) added to raloxifene
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/day) added to alendronate
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/day) switched from raloxifene
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/day) switched from alendronate
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control (raloxifene or alendronate)
Number of subjects: 198
Study: 16093267

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (5 mg Androderm)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 14605927

Group type: EXPERIMENTAL
Intervention: Modified cutting seton
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional cutting seton
Number of subjects: 34
Study: 10953135

Group type: EXPERIMENTAL
Intervention: 1 implant
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 2 implants
Number of subjects: 51
Study: 8793613

Group type: EXPERIMENTAL
Intervention: 25 mg promethazine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: both drugs
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 1616516

Group type: EXPERIMENTAL
Intervention: Activated charcoal 50 gm every hour for 8 hours (cumulative dose 150 gm)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Activated charcoal 25 gm every 2 hours for 8 hours (cumulative dose 150 gm)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Activated charcoal 12.5 gm every hour for 8 hours (cumulative dose 150 gm)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control phase (no activated charcoal, only aminophylline 8 mg/kg)
Number of subjects: 5
Study: 6437264

Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate (200-1600 mg/24 h)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30682069

Group type: EXPERIMENTAL
Intervention: SP‐AQ only
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: SP‐AQ plus LNS
Number of subjects: 7000

Group type: COMPARATOR
Intervention: LNS
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Nutritional status
Number of subjects: 7000
Study: 30107641

Group type: EXPERIMENTAL
Intervention: Single-step nasal spray (SP)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Intramuscular simulated naloxone (IM)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Multi-step atomized nasal spray (AT)
Number of subjects: 138
Study: 25987647

Group type: EXPERIMENTAL
Intervention: ≥5% reduction in sedentary time (N = 27)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0-4.99% reduction in sedentary time (N = 29)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Increase in sedentary time (N = 40)
Number of subjects: 96
Study: 24033356

Group type: EXPERIMENTAL
Intervention: Fasudil (30 mg intravenous administration)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 23421087

Group type: EXPERIMENTAL
Intervention: Oxalin (0.05%)
Number of subjects: 4674
Study: 19427798

Group type: COMPARATOR
Intervention: Ankle brace (lace-up brace)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cryotherapy (ice)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined ankle bracing and joint cooling
Number of subjects: 24
Study: 17663619

Group type: EXPERIMENTAL
Intervention: Face-to-face or Internet intervention
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Daily weighing
Number of subjects: 314
Study: 16105050

Group type: EXPERIMENTAL
Intervention: irbesartan 300 mg once daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: irbesartan 600 mg once daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: irbesartan 900 mg once daily
Number of subjects: 52
Study: 12392585

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 173
Study: 10658441

Group type: EXPERIMENTAL
Intervention: Short-term treatment protocol (STP) with PGE1 alpha-ciclodestrina: 2-hour infusions (20 micrograms in the morning, 40 micrograms in the afternoon on the first day; 60 micrograms b.i.d. on the second day) for 2 days, repeated at weeks 4, 8, 12.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Long-term treatment protocol (LTP) with PGE1 alpha-ciclodestrina: 2-hour infusions (60 micrograms PGE1 alpha-ciclodestrina, 5 days each week for 4 weeks, then twice a week for 4 weeks).
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both STP and LTP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: STP
Number of subjects: 120

Group type: COMPARATOR
Intervention: LTP
Number of subjects: 120